<DOC>
	<DOCNO>NCT01428115</DOCNO>
	<brief_summary>It show emotional health issue , state anxiety , prevalent patient suffer inflammatory bowel disease ( IBD ) compare physically healthy subject . Such finding take consideration make educated guess psychological factor depression anxiety particular interact course Crohns disease . Therefore treatment underlie disease may significant influence level psychological disorder . Several study show treatment tumor necrosis factor alpha ( TNF-α ) antibodies ameliorate emotional/psychological status patient , however impact adalimumab therapy anxiety correlate status inflammatory bowel disease ( IBD ) remain unclear . The primary objective study describe evaluate change level anxiety assess validated patient questionnaires 6 month treatment adalimumab .</brief_summary>
	<brief_title>Reveal Level Anxiety Patients With Crohn 's Disease Receiving Adalimumab</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients Adalimumab ( Humira ) therapy indicate prescribed accord product label meet follow criterion : Male female patient age 18 65 year suffer severe active Crohns Disease , attend routine medical visit . Able complete questionnaire . Patients status active severe Crohns disease require immunosuppressive treatment Patients must fulfil international national guideline use biologic therapy Crohns Disease ( Chest Xray interferon gamma release assay ( IGRA ) PPD ( purify protein derivative ) skin test negative tuberculosis ) . Patients respond despite full adequate course therapy corticosteroid and/or immunosuppressant ; intolerant medical contraindication therapy . Patients prescribed line European Summary Product Characteristics ( SMPC ) The following patient include observational study : Previous therapy TNFα blocker within last 8 week Active Central Nervous System opportunistic infection Central Nervous System malignancy . History Cerebrovascular Accident Abuse illicit substance ( psychoactive drug ) within previous 3 month Change medicationbased treatment generalize anxiety panic disorder , psychiatric disorder No inform consent Contraindication adalimumab ( Humira ) therapy accord SMPC Current plan pregnancy Lactation accord SMPC Planned change site within next 24 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>monoclonal</keyword>
	<keyword>anxiety</keyword>
	<keyword>antibody</keyword>
	<keyword>adalimumab</keyword>
	<keyword>severe crohn 's disease</keyword>
	<keyword>quality life</keyword>
	<keyword>biological product</keyword>
</DOC>